Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
HALOZYME THERAPEUTICS, INC. (HALO)
|
Add to portfolio |
|
|
|
| Price: |
$41.06
| | Metrics |
| OS: |
131.9
|
M
| |
|
|
| Market cap: |
$5.42
|
B
| |
|
|
|
Net debt:
|
$1.27
|
B
| |
|
|
|
EV:
|
$6.69
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 443.3 | 267.6 | 196.0 | 151.9 | 316.6 | 146.7 | 135.1 | 75.3 |
| Revenue growth | 65.7% | 36.5% | 29.1% | -52.0% | 115.8% | 8.6% | 79.3% | 37.5% |
| Cost of goods sold | 81.4 | 43.4 | 45.5 | 10.1 | 31.2 | 33.2 | 29.2 | 22.7 |
| Gross profit | 361.9 | 224.2 | 150.4 | 141.7 | 285.5 | 113.5 | 105.8 | 52.6 |
| Gross margin | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% | 78.3% | 69.8% |
| Selling, general and administrative | 50.3 | 45.7 | 77.3 | 60.8 | 53.8 | 45.9 | 40.0 | 35.9 |
| Research and development | 35.7 | 34.2 | 140.8 | 150.3 | 150.6 | 150.8 | 93.2 | 79.7 |
| EBIT | 275.9 | 144.3 | -67.6 | -69.3 | 81.0 | -83.2 | -27.5 | -63.0 |
| EBIT margin | 62.2% | 53.9% | -34.5% | -45.7% | 25.6% | -56.7% | -20.3% | -83.7% |
| Pre-tax income | 248.5 | 129.3 | -72.3 | -79.8 | 61.6 | -101.9 | -32.2 | -68.4 |
| Income taxes | -154.2 | 0.2 | 0.0 | 0.5 | -1.4 | 1.2 | 0.0 | 0.0 |
| Tax rate | | 0.2% | 0.0% | | | | 0.0% | 0.0% |
| Net income | 402.7 | 129.1 | -72.2 | -80.3 | 63.0 | -103.0 | -32.2 | -68.4 |
| Net margin | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% | -23.9% | -90.8% |
| |
| Diluted EPS | $2.74 | $0.91 | ($0.50) | ($0.56) | $0.45 | ($0.81) | ($0.25) | ($0.56) |
| Shares outstanding (diluted) | 146.8 | 141.5 | 144.3 | 143.6 | 139.1 | 128.0 | 126.7 | 122.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|